Haoyang and PolyU collaborated on human clinical trial protocols published in international academic literature
(Penang, 24th) Haoyang Health Food Industry Co., Ltd. and the University of Science Malaysia have cooperated to launch an 18-month human clinical trial to investigate the effectiveness of supplementing Oat King comprehensive cereals in patients with type 2 diabetes. This human clinical trial was favored by the International Diabetes Journal Publishing House after the official announcement of the research results and was invited to publish the research procedures in the international academic literature “World Journal of Diabetes”, titled “Efficacy of multigrain supplementation in type 2 diabetes mellitus: A pilot study protocol for a randomized intervention trial”.
Mohd Ariffin NA, Mohd Sopian M, Lee LK. Efficacy of multigrain supplementation in type 2 diabetes mellitus: A pilot study protocol for a randomized intervention trial. World J Diabetes 2023; 14(5): 606-616 [DOI: 10.4239/wjd.v14.i5.606].
This document explains in detail the various procedures in this 18-month human clinical trial. In addition to enabling a wide range of readers to understand each detail of the trial more deeply, it is also possible to understand the effect of integrated grains on genotype B. Effectiveness in diabetes.
For more details about the test procedures, please visit: https://www.wjgnet.com/1948-9358/abstract/v14/i5/606.htm
Long-term consumption of high β-glucan Oat King
Sugar friends have good gastrointestinal tolerance
According to the Diabetes Education Handbook 2020 issued by the Malaysian Diabetes Educators Society (Malaysian Diabetes Educators Society), it is estimated that 7 million adults in Malaysia will suffer from diabetes by 2025. According to the survey, one out of every five adults in our country suffers from diabetes, which is a worrying trend.
Haoyang Health Food Industry Co., Ltd. and the University of Science Malaysia signed a human clinical trial agreement in 2020 to jointly explore the effectiveness of Oat King’s comprehensive grain products in improving type 2 diabetes. The research team is led by Dr Li Lijun, Masdullah, Associate Professor Hu Qingyan and Dr Mohd Hafiz, and the trial will last for 18 months.
The clinical trial was divided into two groups, a total of 50 patients with type 2 diabetes participated. Group A included 25 people, who supplemented 60 grams of Oat King every day on the basis of daily drug treatment; group B also included 25 people who only took drug treatment, and the entire supplementary period lasted for 12 weeks. This trial has been approved by the Committee on Human Ethical Medicine (Human Clinical Trials) (No: USM/JEPeM/20030183).
According to the summary of human clinical trials, patients with type 2 diabetes can significantly improve their glycosylated hemoglobin level (HbA1C) when supplemented with 2 packets of Oat King rich in oat β-glucan (Beta-Glucan) every day. Patients also experienced significant reductions in total and LDL cholesterol concentrations over the course of the 12-week trial. In addition, the study found that supplementing with Oat King for up to 12 weeks can help patients effectively reduce total fat and visceral adipose tissue, and improve the body’s antioxidant capacity.
Dr. Li Lijun also said that patients who supplemented with high-β-glucan Oat King also had fewer gastrointestinal side effects, which proves that long-term consumption of high-β-glucan Oat King has good gastrointestinal tolerance. This successful human clinical trial undoubtedly brings a glimmer of hope to the diabetes trend in our country.
For more details, please visit Haoyang Facebook page: